Genetesis is a technology company.
Genetesis is focused on revolutionizing cardiac care through its CardioFlux technology, which non-invasively detects functionally significant ischemia at its earliest stages.
Genetesis has raised $35.0M across 3 funding rounds.
Genetesis has raised $35.0M in total across 3 funding rounds.
Genetesis has raised $35.0M in total across 3 funding rounds.
Genetesis's investors include Alumni Ventures, Cincy Tech, Eclipse Ventures, Mithril Capital Management, OrbiMed, Sonder Capital, TDK Ventures.
Genetesis is a commercial-stage medical technology company developing noninvasive biomagnetic imaging for cardiac diagnostics, specifically the CardioFlux Magnetocardiograph (MCG) paired with the Faraday Analytical Cloud (FAC).[1][2][4] It serves clinicians and hospitals by addressing myocardial ischemia and coronary artery disease triage in acute care settings, such as emergency departments handling eight million annual chest pain visits, aiming to serve as the ultimate rule-out test alongside EKGs and troponins without radiation, exercise, or specialized rooms.[1][4] The platform solves inefficient chest pain triage by delivering quick magnetic field maps processed into actionable insights via cloud-based machine learning, integrating into clinical workflows to reduce ER length of stay; the company has raised over $25M in venture funding, secured FDA 510(k) clearance, and achieved commercial availability.[2][4]
Genetesis was founded in 2013 in Mason, Ohio, by three co-founders: Peeyush Shrivastava (CEO), with 8+ years as a serial medtech entrepreneur and Biomedical Science background; Vineet (COO), expert in medical device lifecycle and commercial strategy; and Emmanuel (CTO), with nearly 10 years in software and IT operations.[2][4][5] The idea emerged from advancing magnetocardiography (MCG)—a 40-year-old technology previously limited by bulky SQUID hardware—into a practical, high-density commercial tool for cardiac care.[2][6] Early days included bootstrapping from Thompson Library in summer 2016, posting "Yes We're Open" notes to build momentum, leading to pivotal FDA clearance for CardioFlux and FAC, plus $9.2M Series B funding in 2020 from TDK Ventures, Mark Cuban Companies, CincyTech, and others.[1][2][4]
Genetesis rides the precision cardiology and noninvasive diagnostics trend, capitalizing on rising demand for radiation-free, rapid triage amid 8M annual U.S. chest pain ER visits and global cardiovascular disease burden.[4] Timing aligns with advances in magnetic sensing (leveraging TDK expertise) and cloud AI, enabling scalable deployment in resource-strapped hospitals post-COVID.[4][6] Market forces like value-based care, ER overcrowding, and medtech investor focus on outcomes favor it, positioning Genetesis to influence ecosystems by standardizing MCG in acute care, potentially freeing hospital resources and improving patient flow.[1][4]
Genetesis is poised for expanded adoption as hospitals prioritize efficient, tech-driven cardiac triage, with next steps likely including broader commercialization, additional FDA indications, and partnerships to embed CardioFlux in workflows.[1][2] Trends like AI-enhanced imaging and precision health will accelerate growth, evolving its influence from niche innovator to standard-of-care enabler in ischemia detection. This builds on its rule-out test ambition, redefining diagnostics from Genetesis's library-start hustle to clinical powerhouse.[2][4]
Genetesis has raised $35.0M across 3 funding rounds. Most recently, it raised $18.0M Series C in October 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Oct 1, 2022 | $18.0M Series C | Alumni Ventures, Cincy Tech, Eclipse Ventures, Mithril Capital Management, OrbiMed, Sonder Capital | |
| Apr 1, 2020 | $9.0M Series B | TDK Ventures | |
| Jun 1, 2018 | $8.0M Series A | Cincy Tech, OrbiMed |